person · Reporting owner

Hill Christopher Scott

Disclosed activity across 2 companies

Tapewire entity: 66149
SEC CIK: 0001641315

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CORE LABORATORIES N VCLB · Entity 11862	SVP & CFO	February 16, 2023	February 21, 2023
Core Laboratories Inc. /DE/CLB · Entity 5382	SVP & CFO	February 12, 2026	February 17, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CORE LABORATORIES N V

Report date February 16, 2023 · Filed February 21, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Performance SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	52,718	Reported balance After 2023-02-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-02-16 · Grant · Acquired 52,718 · Balance 52,718 F1: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.

Filing footnotes · ownership attribution and instrument terms

F1: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period.

F2: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.

Core Laboratories Inc. /DE/

Report date February 12, 2026 · Filed February 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Performance SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	70,008	Reported balance After 2026-02-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-12 · Grant · Acquired 70,008 · Balance 70,008 F2: This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F3: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.
Common StockSEC Table I · non-derivative	Indirect401(k) Plan	59	Reported balance Holding disclosure · report date 2026-02-12 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 59 F1: The Reporting Person's indirect beneficial ownership includes 59 shares of the Issuer's common stock held in the Issuer's 401(k) plan, which were previously reported but were inadvertently omitted from a prior Form 4 filing.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person's indirect beneficial ownership includes 59 shares of the Issuer's common stock held in the Issuer's 401(k) plan, which were previously reported but were inadvertently omitted from a prior Form 4 filing.

F2: This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period.

F3: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 12, 2026 Filed Feb 17, 2026 11:04 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	GrantPerformance Shares · Derivative	70,008	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001193125-26-053598 · ownership.xml · derivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,008 Underlying: Common Stock · 70,008 shares Expires not disclosed F2 · derivative.exercise_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F3 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.expiration_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document
December 31, 2025 Filed Jan 5, 2026 15:17 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	Exercise / conversionPerformance Shares · Derivative	61,417	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001193125-26-002252 · ownership.xml · derivative · entry 3 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025. Read SEC document
December 31, 2025 Filed Jan 5, 2026 15:17 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	Exercise / conversionCommon Stock	61,417	$0.00	$0.00	Disclosure SEC source: 0001193125-26-002252 · ownership.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 31, 2025 Filed Jan 5, 2026 15:17 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	Tax withholdingCommon Stock	32,152	$16.03	$515,396.56	Disclosure SEC source: 0001193125-26-002252 · ownership.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,202 Read SEC document
February 13, 2025 Filed Feb 13, 2025 16:37 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	GrantPerformance Shares · Derivative	68,800	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-019960 · ownership.xml · derivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,800 Underlying: Common Stock · 68,800 shares Expires not disclosed F1 · derivative.exercise_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2025 and ends on December 31, 2027 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on January 1, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2025 and ends on December 31, 2027 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on January 1, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document
December 31, 2024 Filed Jan 3, 2025 16:59 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	Exercise / conversionPerformance Shares · Derivative	23,607	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-001317 · ownership.xml · derivative · entry 3 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,607 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022. The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022. The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024. Read SEC document
December 31, 2024 Filed Jan 3, 2025 16:59 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	Exercise / conversionCommon Stock	23,607	$0.00	$0.00	Disclosure SEC source: 0000950170-25-001317 · ownership.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 31, 2024 Filed Jan 3, 2025 16:59 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	Tax withholdingCommon Stock	14,719	$17.31	$254,785.89	Disclosure SEC source: 0000950170-25-001317 · ownership.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,937 Read SEC document
February 15, 2024 Filed Feb 15, 2024 16:11 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	GrantPerformance Shares · Derivative	79,442	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-24-015888 · ownership.xml · derivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,442 Underlying: Common Stock · 79,442 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.expiration_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document
December 31, 2023 Filed Jan 3, 2024 17:43 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	Exercise / conversionPerformance Shares · Derivative	36,072	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-24-001237 · ownership.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,072 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021. The Company finished in the 81st percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2023. Excess shares that could vest above the 75th percentile are subject to an absolute total shareholder return modifier, which was negative over the relevant performance period, thereby reducing the number of such shares eligible to vest by one-half. Therefore, the performance criteria and requirements for vesting have been satisfied at 106.25% of the target award level, and such number of shares vested on December 31, 2023. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021. The Company finished in the 81st percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2023. Excess shares that could vest above the 75th percentile are subject to an absolute total shareholder return modifier, which was negative over the relevant performance period, thereby reducing the number of such shares eligible to vest by one-half. Therefore, the performance criteria and requirements for vesting have been satisfied at 106.25% of the target award level, and such number of shares vested on December 31, 2023. Read SEC document
December 31, 2023 Filed Jan 3, 2024 17:43 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	Exercise / conversionCommon Stock	36,072	$0.00	$0.00	Disclosure SEC source: 0000950170-24-001237 · ownership.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 31, 2023 Filed Jan 3, 2024 17:43 UTC	Core Laboratories Inc. /DE/ CLB · Entity 5382	Tax withholdingCommon Stock	13,870	$17.66	$244,944.20	Disclosure SEC source: 0000950170-24-001237 · ownership.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,374 Read SEC document
December 31, 2023 Filed Jan 8, 2024 14:49 UTC Amendment	Core Laboratories Inc. /DE/ CLB · Entity 5382	Tax withholdingCommon Stock	14,195	$17.66	$250,683.70	Disclosure SEC source: 0000950170-24-002890 · ownership.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,049 F1 · shares: The original Form 4, filed on January 3, 2024, is being amended by this Form 4 amendment to correct an administrative error of the issuer, whereupon the number of shares withheld to satisfy tax withholding obligations upon vesting of certain restricted performance shares was misreported as 13,870 shares. The corrected transaction reflects an increase of 325 shares withheld by the issuer as a result such vesting and a corresponding reduction in the number of shares beneficially owned by the reporting person. Read SEC document
February 16, 2023 Filed Feb 21, 2023 15:20 UTC	CORE LABORATORIES N V CLB · Entity 11862	GrantPerformance Shares · Derivative	52,718	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-23-011099 · doc4.xml · derivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,718 Underlying: Common Shares · 52,718 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.expiration_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document
December 31, 2022 Filed Jan 4, 2023 16:55 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionPerformance Shares · Derivative	31,688	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-23-001028 · doc4.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 31,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2020, as disclosed in the Reporting Person's Form 4 filing on February 12, 2020. All requirements for 100% vesting have been met and thus the restricted shares vested on December 31, 2022 at the conclusion of the performance period. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2020, as disclosed in the Reporting Person's Form 4 filing on February 12, 2020. All requirements for 100% vesting have been met and thus the restricted shares vested on December 31, 2022 at the conclusion of the performance period. Read SEC document
December 31, 2022 Filed Jan 4, 2023 16:55 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionCommon Shares	31,688	$0.00	$0.00	Disclosure SEC source: 0001209191-23-001028 · doc4.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 31, 2022 Filed Jan 4, 2023 16:55 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	12,470	$20.27	$252,766.90	Disclosure SEC source: 0001209191-23-001028 · doc4.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,172 Read SEC document
February 17, 2022 Filed Feb 17, 2022 17:08 UTC	CORE LABORATORIES N V CLB · Entity 11862	GrantPerformance Shares · Derivative	43,236	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-22-010862 · doc4.xml · derivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,236 Underlying: Common Shares · 43,236 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2022 and ends on December 31, 2024 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause, termination by the employee for "good reason" (as defined in the employee's employment agreement), or retirement by the employee upon having reached 62 years of age. The shares would vest, if at all, at the end of the Performance Period as follows: (i) 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group ("BPG"); (ii) 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG; or (iii) 150% of the award will vest if the Company is the top performing ROIC company of the BPG, all as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Share Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2022 and ends on December 31, 2024 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause, termination by the employee for "good reason" (as defined in the employee's employment agreement), or retirement by the employee upon having reached 62 years of age. The shares would vest, if at all, at the end of the Performance Period as follows: (i) 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group ("BPG"); (ii) 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG; or (iii) 150% of the award will vest if the Company is the top performing ROIC company of the BPG, all as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.expiration_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Share Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document
December 31, 2021 Filed Jan 4, 2022 17:55 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionPerformance Shares · Derivative	23,529	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-22-001068 · doc4.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 23,529 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vesting were awarded as restricted performance shares in February 2019 as reported in the Form 4 filing on February 14, 2019. This filing states that 50% of the restricted performance shares will vest at the end of the Performance Period if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th ROIC percentile of the BPG and 150% of the award will vest if the Company is the top performing company of the BPG. The Company was the top performing ROIC company as of the end of the performance period and as such the performance criteria and all requirements for full vesting have been met and thus the shares granted in February 2019 vested on December 31, 2021, at the conclusion of the performance period. F1 · derivative.expiration_date: The shares vesting were awarded as restricted performance shares in February 2019 as reported in the Form 4 filing on February 14, 2019. This filing states that 50% of the restricted performance shares will vest at the end of the Performance Period if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th ROIC percentile of the BPG and 150% of the award will vest if the Company is the top performing company of the BPG. The Company was the top performing ROIC company as of the end of the performance period and as such the performance criteria and all requirements for full vesting have been met and thus the shares granted in February 2019 vested on December 31, 2021, at the conclusion of the performance period. Read SEC document
December 31, 2021 Filed Jan 4, 2022 17:55 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionCommon Shares	23,529	$0.00	$0.00	Disclosure SEC source: 0001209191-22-001068 · doc4.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 31, 2021 Filed Jan 4, 2022 17:55 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	9,259	$22.31	$206,568.29	Disclosure SEC source: 0001209191-22-001068 · doc4.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,954 Read SEC document
February 19, 2021 Filed Feb 23, 2021 16:42 UTC	CORE LABORATORIES N V CLB · Entity 11862	GrantPerformance Shares · Derivative	33,950	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-21-013240 · doc4.xml · derivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,950 Underlying: Common Shares · 33,950 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2021 and ends on December 31, 2023 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG all as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Shareholder Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2021 and ends on December 31, 2023 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG all as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.expiration_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Shareholder Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document
December 31, 2020 Filed Jan 5, 2021 16:21 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionPerformance Shares · Derivative	2,600	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-21-001047 · doc4.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These awards vested at the end of a three-year performance period that began on January 1, 2018 and ended December 31, 2020 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. F1 · derivative.expiration_date: These awards vested at the end of a three-year performance period that began on January 1, 2018 and ended December 31, 2020 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. Read SEC document
December 31, 2020 Filed Jan 5, 2021 16:21 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	1,024	$26.51	$27,146.24	Disclosure SEC source: 0001209191-21-001047 · doc4.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,684 Read SEC document
December 31, 2020 Filed Jan 5, 2021 16:21 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionCommon Shares	2,600	$0.00	$0.00	Disclosure SEC source: 0001209191-21-001047 · doc4.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2020 Filed Apr 2, 2020 14:56 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionRestricted Shares · Derivative	53	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-022444 · doc4.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 53 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document
April 01, 2020 Filed Apr 2, 2020 14:56 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	24	$9.49	$227.76	Disclosure SEC source: 0001209191-20-022444 · doc4.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,108 Read SEC document
April 01, 2020 Filed Apr 2, 2020 14:56 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionCommon Shares	53	$0.00	$0.00	Disclosure SEC source: 0001209191-20-022444 · doc4.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 11, 2020 Filed Feb 12, 2020 17:22 UTC	CORE LABORATORIES N V CLB · Entity 11862	GrantPerformance Shares · Derivative	31,688	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-008888 · doc4.xml · derivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,688 Underlying: Common Shares · 31,688 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2020 and ends on December 31, 2022 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG. F2 · derivative.exercise_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Shareholder Return for the 2020 Performance Period is negative, all as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If the minimum performance criteria is not met, then no shares shall vest and the award shall be forfeited. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2020 and ends on December 31, 2022 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG. F2 · derivative.expiration_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Shareholder Return for the 2020 Performance Period is negative, all as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If the minimum performance criteria is not met, then no shares shall vest and the award shall be forfeited. Read SEC document
December 31, 2019 Filed Jan 3, 2020 16:09 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionPerformance Shares · Derivative	2,400	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-000804 · doc4.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These awards vested at the end of a three-year performance period that began on January 1, 2017 and ended December 31, 2019 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. F1 · derivative.expiration_date: These awards vested at the end of a three-year performance period that began on January 1, 2017 and ended December 31, 2019 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. Read SEC document
December 31, 2019 Filed Jan 3, 2020 16:09 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	945	$37.67	$35,598.15	Disclosure SEC source: 0001209191-20-000804 · doc4.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,079 Read SEC document
December 31, 2019 Filed Jan 3, 2020 16:09 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionCommon Shares	2,400	$0.00	$0.00	Disclosure SEC source: 0001209191-20-000804 · doc4.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2019 Filed Apr 2, 2019 16:10 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionRestricted Shares · Derivative	53	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001000229-19-000048 · wf-form4_155423581124804.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53 Underlying: Common Shares · 53 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document
April 01, 2019 Filed Apr 2, 2019 16:10 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	25	$68.93	$1,723.25	Disclosure SEC source: 0001000229-19-000048 · wf-form4_155423581124804.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,624 Read SEC document
April 01, 2019 Filed Apr 2, 2019 16:10 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionCommon Shares	53	$0.00	$0.00	Disclosure SEC source: 0001000229-19-000048 · wf-form4_155423581124804.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2019 Filed Mar 5, 2019 16:18 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionRestricted Shares · Derivative	100	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001000229-19-000029 · wf-form4_155182071943198.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106 Underlying: Common Shares · 100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document
March 01, 2019 Filed Mar 5, 2019 16:18 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	46	$67.37	$3,099.02	Disclosure SEC source: 0001000229-19-000029 · wf-form4_155182071943198.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,596 Read SEC document
March 01, 2019 Filed Mar 5, 2019 16:18 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionCommon Shares	100	$0.00	$0.00	Disclosure SEC source: 0001000229-19-000029 · wf-form4_155182071943198.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 12, 2019 Filed Feb 14, 2019 16:26 UTC	CORE LABORATORIES N V CLB · Entity 11862	GrantPerformance Shares · Derivative	15,684	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001000229-19-000026 · wf-form4_155017958545108.xml · derivative · entry 1 Hill Christopher Scott · CIK 0001641315 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,684 Underlying: Common Shares · 15,684 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2019 and ends on December 31, 2021 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing company of the BPG, all as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If the minimum performance criteria is not met, then no shares shall vest and the award shall be forfeited. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2019 and ends on December 31, 2021 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing company of the BPG, all as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If the minimum performance criteria is not met, then no shares shall vest and the award shall be forfeited. Read SEC document
December 31, 2018 Filed Jan 3, 2019 16:16 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionPerformance Shares · Derivative	3,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001000229-19-000006 · wf-form4_154655016149671.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These awards vested at the end of a three-year performance period that began on January 1, 2016 and ended on December 31, 2018 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. F1 · derivative.expiration_date: These awards vested at the end of a three-year performance period that began on January 1, 2016 and ended on December 31, 2018 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. Read SEC document
December 31, 2018 Filed Jan 3, 2019 16:16 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	1,181	$59.66	$70,458.46	Disclosure SEC source: 0001000229-19-000006 · wf-form4_154655016149671.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,542 Read SEC document
December 31, 2018 Filed Jan 3, 2019 16:16 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionCommon Shares	3,000	$0.00	$0.00	Disclosure SEC source: 0001000229-19-000006 · wf-form4_154655016149671.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 01, 2018 Filed Sep 5, 2018 17:17 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionRestricted Shares · Derivative	125	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001000229-18-000106 · wf-form4_153618220338931.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206 Underlying: Common Shares · 125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.exercise_date: Multiple restricted share grants are included in this total. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.expiration_date: Multiple restricted share grants are included in this total. Read SEC document
September 01, 2018 Filed Sep 5, 2018 17:17 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	49	$114.55	$5,612.95	Disclosure SEC source: 0001000229-18-000106 · wf-form4_153618220338931.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,723 Read SEC document
September 01, 2018 Filed Sep 5, 2018 17:17 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionCommon Shares	125	$0.00	$0.00	Disclosure SEC source: 0001000229-18-000106 · wf-form4_153618220338931.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2018 Filed Apr 3, 2018 17:27 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionRestricted Shares · Derivative	53	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001000229-18-000056 · wf-form4_152279084158042.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331 Underlying: Common Shares · 53 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.exercise_date: Multiple restricted share grants are included in this total. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.expiration_date: Multiple restricted share grants are included in this total. Read SEC document
April 01, 2018 Filed Apr 3, 2018 17:27 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	16	$108.22	$1,731.52	Disclosure SEC source: 0001000229-18-000056 · wf-form4_152279084158042.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,647 Read SEC document
April 01, 2018 Filed Apr 3, 2018 17:27 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionCommon Shares	53	$0.00	$0.00	Disclosure SEC source: 0001000229-18-000056 · wf-form4_152279084158042.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2018 Filed Mar 9, 2018 18:33 UTC	CORE LABORATORIES N V CLB · Entity 11862	Exercise / conversionRestricted Shares · Derivative	100	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001000229-18-000039 · wf-form4_152063842416905.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384 Underlying: Common Shares · 100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.exercise_date: Multiple restricted share grants are included in this total. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.expiration_date: Multiple restricted share grants are included in this total. Read SEC document
March 01, 2018 Filed Mar 9, 2018 18:33 UTC	CORE LABORATORIES N V CLB · Entity 11862	Tax withholdingCommon Shares	30	$102.99	$3,089.70	Disclosure SEC source: 0001000229-18-000039 · wf-form4_152063842416905.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,610 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.